Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Gwenn S. Smith, PhD: Applications of Neuroreceptor Imaging to Psychiatry Research
1
x
$
30.00
Carlos A. Zarate, MD: Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders
1
x
$
30.00
Patient Response Trajectories in Major Depressive Disorder
1
x
$
30.00
Gender-Specific Differences in Depression and Treatment Response
1
x
$
30.00
Graeme F. Mason, PhD: Magnetic Resonance Spectroscopy for Studies of Neurotransmission in Vivo
1
x
$
30.00
David C. Steffens, MD, MHS: The Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) Approach
1
x
$
30.00
Donald S. Robinson, MD: Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials
1
x
$
30.00
Efficacy of Omega-3 Fatty Acids in Mood Disorders
1
x
$
30.00
Desvenlafaxine and Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome P450 and P-Glycoprotein Activities
1
x
$
30.00
View Cart
Checkout
Home
adam-d-shilling
“Desvenlafaxine and Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome P450 and P-Glycoprotein Activities” has been added to your cart.
View cart
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Desvenlafaxine and Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome P450 and P-Glycoprotein Activities
$
30.00
Add to cart
Details
Page load link
Go to Top
